ETF Fundamental Report for IWM

Validea's fundamental report on the iShares Russell 2000 ETF (IWM), classified as a Mid-Cap Value ETF, details its factor exposures and portfolio composition. IWM scores 62 for Value, but notably low for Quality (7) and Low Volatility (14), with Momentum at 39. Its largest sector exposure is Services, with Biotechnology & Drugs as its leading industry, providing institutional investors insight into its factor biases and sector concentration.

Analysis

Validea's fundamental report on the iShares Russell 2000 ETF (IWM) provides a clear quantitative assessment of its factor exposures, revealing a profile that diverges from what its 'Mid-Cap Value' classification might imply. The ETF exhibits a moderate exposure to the Value factor with a score of 62 out of 99. More significant, however, are its exceptionally low scores in Quality (7) and Low Volatility (14), indicating that its underlying portfolio consists predominantly of companies with weaker fundamental characteristics and higher price volatility. The Momentum score is also low at 39, suggesting the constituent stocks are not currently in a strong uptrend. The portfolio's composition, with the Services sector and specifically the Biotechnology & Drugs industry as its largest exposures, likely explains this factor profile, as biotech is often characterized by speculative, pre-profitability companies, contributing to low quality and high volatility metrics.

Key Decisions for Investors

• Investors seeking high-quality or stable equity exposure should exercise caution, as IWM's extremely low Quality (7) and Low Volatility (14) scores signal a portfolio skewed towards speculative and fundamentally weaker companies.
• While classified as a value ETF, the moderate Value score of 62 suggests it is not a pure-play value instrument; therefore, investors with a strict value mandate should consider if this level of exposure meets their strategy's requirements.
• Portfolio managers could use IWM for tactical exposure to US small-cap risk and cyclicality, but the significant concentration in the volatile Biotechnology & Drugs industry must be actively managed as a key sector-specific risk.
• Given the low Momentum score of 39, trend-following investors may find IWM unattractive, as its constituents currently lack positive price momentum.